{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:45:48Z","timestamp":1792169148117,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04296-0","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:57:01Z","timestamp":1792166221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-surgical management of thyroid eye disease: a pilot survey of oculoplastic surgeons"],"prefix":"10.1007","volume":"46","author":[{"given":"Shiqi","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"4296_CR1","unstructured":"Shah SS, Stokkermans TJ, Patel BC. Thyroid Eye Disease. 2025 Nov 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan\u2013. PMID: 35881739."},{"issue":"7","key":"4296_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S2213-8587(25)00066-X","volume":"13","author":"WM Wiersinga","year":"2025","unstructured":"Wiersinga WM, Eckstein AK, \u017darkovi\u0107 M (2025) Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 13(7):600\u2013614. https:\/\/doi.org\/10.1016\/S2213-8587(25)00066-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"4296_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3341\/kjo.2024.0031","volume":"38","author":"JW Park","year":"2024","unstructured":"Park JW, Yoon JS (2024) A review of novel medical treatments for thyroid eye disease. Korean J Ophthalmol 38(3):249\u2013259. https:\/\/doi.org\/10.3341\/kjo.2024.0031","journal-title":"Korean J Ophthalmol"},{"issue":"10","key":"4296_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1089\/thy.2023.0167","volume":"33","author":"D Toro-Tobon","year":"2023","unstructured":"Toro-Tobon D, Rachmasari KN, Bradley EA, Wagner LH, Tooley AA, Stokken JK, Stan MN (2023) Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease. Thyroid 33(10):1237\u20131244. https:\/\/doi.org\/10.1089\/thy.2023.0167","journal-title":"Thyroid"},{"issue":"2","key":"4296_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","volume":"16","author":"PN Taylor","year":"2020","unstructured":"Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M (2020) New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 16(2):104\u2013116. https:\/\/doi.org\/10.1038\/s41574-019-0305-4","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"4296_CR6","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","volume":"11","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts I, Salvi M, Stan MN (2022) Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid 11(6):e220189. https:\/\/doi.org\/10.1530\/ETJ-22-0189","journal-title":"Thyroid"},{"issue":"4","key":"4296_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","volume":"140","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, Qadeer RA, Cameron C (2022) Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison. JAMA Ophthalmol 140(4):328\u2013335. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.6284","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"4296_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ (2021) Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 9(6):360\u2013372. https:\/\/doi.org\/10.1016\/S2213-8587(21)00056-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"4296_CR9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.ajo.2014.02.044","volume":"157","author":"PN Shams","year":"2014","unstructured":"Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ (2014) Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 157(6):1299\u20131305. https:\/\/doi.org\/10.1016\/j.ajo.2014.02.044","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"4296_CR10","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","volume":"108","author":"GJ Kahaly","year":"2023","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, Srinivasan A, Hadjiiski L, Jordan D, Bradley EA et al (2023) Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab 108(12):3122\u20133134. https:\/\/doi.org\/10.1210\/clinem\/dgad381","journal-title":"J Clin Endocrinol Metab"},{"key":"4296_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, Espa\u00f1a Gregori E, Sales-Sanz M, Maneiro J, Tome Martinez de Rituerto MA, Pampin EP, Alvarez A, Lopez AR, Troyano J, Ni\u00f1o C, Vico E, Monta\u00f1ez Zorrilla MC, Sanz MS, Mart\u00edn Ucero AM, Revenga M, Gregori EE, P\u00e9rez Lazaro AM, Todoli JA, Gonzalez Alejos AM, D\u00edaz C, Cubero Marcos JM, Polo AD, Lavilla L, Gin\u00e9s CP, Cabello ADE, G\u00f3mez Escobar AJ, Sarabia FN, Hern\u00e1ndez TM, Sorroche MG, Navarro E, Rubio E, Bland\u00f3n RV, Maiquez MP (2018) Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 195:181\u2013190. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"4296_CR12","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marin\u00f2 M, Vaidya B, Wiersinga WM, EUGOGO (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185(4):G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"4296_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3109\/01676830.2014.938168","volume":"33","author":"G Sundar","year":"2014","unstructured":"Sundar G, Chiam N, Lun K, Koh V (2014) Survey of common practices among oculofacial surgeons in the Asia-Pacific region: Graves\u2019 orbitopathy. Orbit 33(5):319\u2013325. https:\/\/doi.org\/10.3109\/01676830.2014.938168","journal-title":"Orbit"},{"issue":"18","key":"4296_CR14","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376(18):1748\u20131761. https:\/\/doi.org\/10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"issue":"6","key":"4296_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3341\/kjo.2025.0108","volume":"39","author":"D Surl","year":"2025","unstructured":"Surl D, Ko J, Yang J, Yoon JS (2025) A nationwide survey by the Korean Society of Ophthalmic Plastic and Reconstructive Surgery (KSOPRS) on the management of thyroid eye disease in South Korea. Korean J Ophthalmol 39(6):532\u2013541. https:\/\/doi.org\/10.3341\/kjo.2025.0108","journal-title":"Korean J Ophthalmol"},{"issue":"1","key":"4296_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89063-4","volume":"15","author":"Z Huang","year":"2025","unstructured":"Huang Z, Xu M, Zhang W, Song X (2025) Triamcinolone acetonide and botulinum toxin A for upper eyelid retraction in thyroid-associated ophthalmopathy. Sci Rep 15(1):5103. https:\/\/doi.org\/10.1038\/s41598-025-89063-4","journal-title":"Sci Rep"},{"issue":"3","key":"4296_CR17","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s12020-023-03672-5","volume":"84","author":"C Wang","year":"2024","unstructured":"Wang C, Qiao J, Liu S, Piao S, Zhou Y, Hu Y, Wan C, Sun Y, Ning H, Chen L et al (2024) Selenium in the treatment of mild-to-moderate Graves\u2019 orbitopathy: a 5-year prospective controlled cohort study. Endocrine 84(3):1072\u20131080. https:\/\/doi.org\/10.1007\/s12020-023-03672-5","journal-title":"Endocrine"},{"issue":"4","key":"4296_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaophthalmol.2024.6337","volume":"143","author":"HY Ahn","year":"2025","unstructured":"Ahn HY, Lee MJ, Jung KY, Kim HJ, Jung EH, Chung CW, Kim K, Jang J, Park YJ, Lee JK, Cho SW (2025) Selenium vs control for Graves ophthalmopathy in a selenium-sufficient area: a randomized clinical trial. JAMA Ophthalmol 143(4):287\u2013294. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.6337","journal-title":"JAMA Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04296-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04296-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04296-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:57:02Z","timestamp":1792166222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04296-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4296"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04296-0","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Capital Medical University Afflicted Beijing Tongren Hospital approved the study (TRECKY2018-056-GZ(2022)\u2212\u200907).\u00a0Informed consent to participate was obtained from all of the participants in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"423"}}